Latest Eczema vaccinatum Stories
KVISTGARD, Denmark, February 1, 2011 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that it has completed a clinical Phase 2 trial of its smallpox vaccine, IMVAMUNE(R), in individuals suffering from atopic dermatitis (a.k.a. eczema).
A promising antimicrobial agent already known to kill bacteria can also kill viruses and stimulate the innate immune system, according to researchers at National Jewish Health.
Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.
NEW YORK (Reuters Health) - About three quarters of patients with monkeypox have affected lymph nodes, a condition that is rare in cases of smallpox or chicken pox, investigators report in two articles in the journal Clinical Infectious Diseases.
Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It is well-known for its role in eradicating smallpox. It was the first human disease to to successfully be eradicated by science. The World Health Organization was the one who completed the endeavor. The vaccinia virus saw renewed interest in the early 21st century due to concerns about the smallpox virus being used as an agent for bioterrorism. They can be divided into four types:...
- An armed gangster.